But though inhibiting ABC transporters has still not been shown to be effective in clinical drug delivery, they have been a valuable resource in furthering our understanding of ABC transporter function and multidrug resistance in cancer, glioma, and other CNS pathologies, as well as their implications at the blood–brain interface [38]. Here, ABCG2 is linked to central nervous system cancer.